LekhaMikkilineniMD

Oncology • Stanford, CA

Hematologic Oncology

Assistant Professor, BMT & Cell Therapy- Stanford University

Join to view full profile

Dr. Mikkilineni is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mikkilineni's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Summary

I am an oncologist who focuses on conducting cellular therapy clinical trials for multiple myeloma.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2013 - 2016
Tulane University School of MedicineClass of 2013

Certifications & Licensure

CA State Medical License 2022 - 2026
MD State Medical License 2016 - 2023
PA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CCF-ASCO Young Investigator Award ASCO; Funded by NIH, 2019
Clinical Training Research Institute American Society of Hematology, 2018

Clinical Trials

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Start of enrollment: 2010 Aug 04
Completed
Phase 1
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies Start of enrollment: 2015 Sep 24
Enrolling by invitation
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies Start of enrollment: 2016 Jan 21
Completed
Phase 1
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Start of enrollment: 2017 Mar 17
Completed
Phase 1
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma Start of enrollment: 2018 Sep 14
Active, not recruiting
Phase 1
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Start of enrollment: 2019 Jun 13
Completed
Phase 1
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Start of enrollment: 2019 Dec 20
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

7 citations
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet H Kocoglu
Blood. 2025-01-02
CAR T-cell therapy to treat multiple myeloma: current state and future directions.
Siddhartha Thammineni Reddy, Hitomi Hosoya, Lekha Mikkilineni
Cancer Metastasis Reviews. 2024-12-03
A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.
Sushma Bharadwaj, Robert Lowsky, Lekha Mikkilineni, Melody Smith, Wen-Kai Weng
Journal of Cancer Education. 2024-11-27

Lectures

Infectious Complications Associated with CAR T-Cell Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019